vs
Orthofix Medical Inc.（OFIX）与RESOURCES CONNECTION, INC.（RGP）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是RESOURCES CONNECTION, INC.的1.9倍（$219.9M vs $117.7M），Orthofix Medical Inc.净利率更高（-1.0% vs -10.8%，领先9.7%），Orthofix Medical Inc.同比增速更快（2.0% vs -19.2%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $15.6M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -11.8%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
RGP原名 Resources Global Professionals，是 Resources Connection, Inc. 的核心运营主体，面向全球客户提供多领域专业咨询服务，覆盖财务会计、信息管理、治理风险合规、人力资本、法务监管、企业咨询与重组、战略传播以及供应链管理等板块。
OFIX vs RGP — 直观对比
营收规模更大
OFIX
是对方的1.9倍
$117.7M
营收增速更快
OFIX
高出21.1%
-19.2%
净利率更高
OFIX
高出9.7%
-10.8%
自由现金流更多
OFIX
多$1.3M
$15.6M
两年增速更快
OFIX
近两年复合增速
-11.8%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $117.7M |
| 净利润 | $-2.2M | $-12.7M |
| 毛利率 | 71.1% | 37.1% |
| 营业利润率 | 0.2% | -10.3% |
| 净利率 | -1.0% | -10.8% |
| 营收同比 | 2.0% | -19.2% |
| 净利润同比 | 92.4% | 81.6% |
| 每股收益（稀释后） | $-0.05 | $-0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXRGP
| Q4 25 | $219.9M | $117.7M | ||
| Q3 25 | $205.6M | $120.2M | ||
| Q2 25 | $203.1M | $139.3M | ||
| Q1 25 | $193.6M | $129.4M | ||
| Q4 24 | $215.7M | $145.6M | ||
| Q3 24 | $196.6M | $136.9M | ||
| Q2 24 | $198.6M | $148.2M | ||
| Q1 24 | $188.6M | $151.3M |
净利润OFIXRGP
| Q4 25 | $-2.2M | $-12.7M | ||
| Q3 25 | $-22.8M | $-2.4M | ||
| Q2 25 | $-14.1M | $-73.3M | ||
| Q1 25 | $-53.1M | $-44.1M | ||
| Q4 24 | $-29.1M | $-68.7M | ||
| Q3 24 | $-27.4M | $-5.7M | ||
| Q2 24 | $-33.4M | $10.5M | ||
| Q1 24 | $-36.0M | $2.5M |
毛利率OFIXRGP
| Q4 25 | 71.1% | 37.1% | ||
| Q3 25 | 72.2% | 39.5% | ||
| Q2 25 | 68.7% | 40.2% | ||
| Q1 25 | 62.8% | 35.1% | ||
| Q4 24 | 69.0% | 38.5% | ||
| Q3 24 | 68.7% | 36.5% | ||
| Q2 24 | 67.8% | 40.2% | ||
| Q1 24 | 67.5% | 37.0% |
营业利润率OFIXRGP
| Q4 25 | 0.2% | -10.3% | ||
| Q3 25 | -8.3% | -1.7% | ||
| Q2 25 | -7.9% | -47.0% | ||
| Q1 25 | -25.2% | -38.4% | ||
| Q4 24 | -5.3% | -52.7% | ||
| Q3 24 | -9.6% | -3.5% | ||
| Q2 24 | -12.5% | 7.6% | ||
| Q1 24 | -15.6% | 2.8% |
净利率OFIXRGP
| Q4 25 | -1.0% | -10.8% | ||
| Q3 25 | -11.1% | -2.0% | ||
| Q2 25 | -6.9% | -52.6% | ||
| Q1 25 | -27.4% | -34.0% | ||
| Q4 24 | -13.5% | -47.2% | ||
| Q3 24 | -13.9% | -4.2% | ||
| Q2 24 | -16.8% | 7.1% | ||
| Q1 24 | -19.1% | 1.7% |
每股收益（稀释后）OFIXRGP
| Q4 25 | $-0.05 | $-0.38 | ||
| Q3 25 | $-0.57 | $-0.07 | ||
| Q2 25 | $-0.36 | $-2.21 | ||
| Q1 25 | $-1.35 | $-1.34 | ||
| Q4 24 | $-0.76 | $-2.08 | ||
| Q3 24 | $-0.71 | $-0.17 | ||
| Q2 24 | $-0.88 | $0.31 | ||
| Q1 24 | $-0.95 | $0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $89.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $194.6M |
| 总资产 | $850.6M | $289.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXRGP
| Q4 25 | $82.0M | $89.8M | ||
| Q3 25 | $62.9M | $77.5M | ||
| Q2 25 | $65.6M | $86.1M | ||
| Q1 25 | $58.0M | $72.5M | ||
| Q4 24 | $83.2M | $78.2M | ||
| Q3 24 | $30.1M | $89.6M | ||
| Q2 24 | $26.4M | $108.9M | ||
| Q1 24 | $27.0M | $113.8M |
总债务OFIXRGP
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXRGP
| Q4 25 | $450.0M | $194.6M | ||
| Q3 25 | $442.5M | $206.4M | ||
| Q2 25 | $458.3M | $207.1M | ||
| Q1 25 | $458.3M | $277.8M | ||
| Q4 24 | $503.1M | $325.7M | ||
| Q3 24 | $525.9M | $407.2M | ||
| Q2 24 | $546.0M | $418.8M | ||
| Q1 24 | $570.3M | $414.9M |
总资产OFIXRGP
| Q4 25 | $850.6M | $289.3M | ||
| Q3 25 | $832.6M | $287.2M | ||
| Q2 25 | $837.2M | $304.7M | ||
| Q1 25 | $823.1M | $375.6M | ||
| Q4 24 | $893.3M | $424.9M | ||
| Q3 24 | $867.9M | $512.9M | ||
| Q2 24 | $882.0M | $510.9M | ||
| Q1 24 | $906.0M | $523.2M |
负债/权益比OFIXRGP
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $15.9M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $15.6M |
| 自由现金流率自由现金流/营收 | 7.6% | 13.2% |
| 资本支出强度资本支出/营收 | 4.9% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $24.3M |
8季度趋势，按日历期对齐
经营现金流OFIXRGP
| Q4 25 | $27.7M | $15.9M | ||
| Q3 25 | $12.4M | $-7.8M | ||
| Q2 25 | $11.6M | $16.8M | ||
| Q1 25 | $-18.4M | $659.0K | ||
| Q4 24 | $23.7M | $1.8M | ||
| Q3 24 | $11.7M | $-309.0K | ||
| Q2 24 | $9.0M | $3.2M | ||
| Q1 24 | $-18.6M | $20.5M |
自由现金流OFIXRGP
| Q4 25 | $16.8M | $15.6M | ||
| Q3 25 | $2.5M | $-8.0M | ||
| Q2 25 | $4.5M | $16.5M | ||
| Q1 25 | $-25.1M | $238.0K | ||
| Q4 24 | $15.2M | $61.0K | ||
| Q3 24 | $6.3M | $-575.0K | ||
| Q2 24 | $-360.0K | $3.0M | ||
| Q1 24 | $-29.1M | $20.4M |
自由现金流率OFIXRGP
| Q4 25 | 7.6% | 13.2% | ||
| Q3 25 | 1.2% | -6.6% | ||
| Q2 25 | 2.2% | 11.8% | ||
| Q1 25 | -13.0% | 0.2% | ||
| Q4 24 | 7.0% | 0.0% | ||
| Q3 24 | 3.2% | -0.4% | ||
| Q2 24 | -0.2% | 2.1% | ||
| Q1 24 | -15.4% | 13.5% |
资本支出强度OFIXRGP
| Q4 25 | 4.9% | 0.3% | ||
| Q3 25 | 4.8% | 0.1% | ||
| Q2 25 | 3.5% | 0.2% | ||
| Q1 25 | 3.5% | 0.3% | ||
| Q4 24 | 4.0% | 1.2% | ||
| Q3 24 | 2.7% | 0.2% | ||
| Q2 24 | 4.7% | 0.1% | ||
| Q1 24 | 5.6% | 0.1% |
现金转化率OFIXRGP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.30× | ||
| Q1 24 | — | 8.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
RGP
| US | $93.7M | 80% |
| Non Us | $24.0M | 20% |
